Cetera Investment Advisers
SUPN icon

Cetera Investment Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Cetera Investment Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,135
Closed -$255K – 4955
2025
Q4 		$255K Buy
+5,135
New +$250K ﹤0.01% 4041

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Investment Advisers's SUPN Position: Q1 2026 in Review

Cetera Investment Advisers sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 5,135 shares — an estimated $255K sold.

Cetera Investment Advisers first reported a position in SUPN in Q4 2025 and held it in 1 quarter. The position peaked at $255K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Cetera Investment Advisers reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 5,135 Supernus Pharmaceuticals shares in Q1 2026, an estimated $255K.
  • Cetera Investment Advisers first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Cetera Investment Advisers's Supernus Pharmaceuticals position peaked at $255K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.